

Certificate of Analysis

FGFR2, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-617, 14-617-K, 14-617M

Parent Lot # 25722U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal, 6His-tagged, recombinant, human FGFR2, amino acids 456–770, expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA-agarose. Purity 90% by SDS-PAGE and Coomassie blue staining. MW = 38.1kDa.

Specific Activity (Parent lot# 25722U): 1188U/mg, where one unit of FGFR2, active activity is defined as 1nmol phosphate incorporated into 0.1mg/ml poly(Glu, Tyr) (4:1) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 1.707mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.03% Brij-35, 0.1mM EGTA, 270mM sucrose, 0.2mM PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 1.42–2.85ng of this lot of enzyme phosphorylated 0.1mg/ml poly(Glu, Tyr) (4:1) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as FGFR2 with the translated native sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Poly(Glu, Tyr) (4:1):** Use at a final concentration of 0.1mg/ml. Make up a 1mg/ml stock. Use 2.5µl of stock per assay point.
3. **Manganese Chloride (MnCl₂):** Use at a final concentration of 2.5mM. Make up a 25mM stock. Use 2.5µl of stock per assay point.
4. **FGFR2, active:** Dilute with 20mM MOPS/NaOH pH 7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 1.42–2.85ng per assay point.
5. **[γ-³³P]ATP:** 2.5 x magnesium acetate/[γ-³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl **poly(Glu, Tyr) (4:1)**.
3. Add **2.5µl (1.42–2.85ng) FGFR2, active**.
4. Add 2.5µl of dH₂O.
5. Add 2.5µl of 25mM MnCl₂.
6. Add 10µl of diluted [γ-³³P]ATP mixture.
7. Incubate for 10 minutes at 30°C.
8. Stop the reaction by adding 5µl of 3% phosphoric acid.
9. Transfer a 10µl aliquot onto the appropriate area of a **Filtermat A**.
10. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
11. Wash the filtermat once for 2 minutes with methanol.
12. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
13. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

FGFR2 Sequence Information

<u>Protein</u>	human FGFR2
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	D16 of the recombinant protein is equivalent to D456 of human FGFR2
<u>Accession number</u>	GenBank NM_000141

Recombinant FGFR2 amino acid sequence:

```

1  MHHHHHHEFK  GLRRQDTPML  AGVSEYELPE  DPKWEFPRDK  LTLGKPLGEG  CFGQVVMAEA
61  VGIDKDKPKE  AVTVAVKMLK  DDATEKDLS  LVSEMEMMKM  IGKHKNIINL  LGACTQDGPL
121 YVIVEYASKG  NLREYLRRAR  PPGMEYSYDI  NRVPEEQMTF  KDLVSCTYQL  ARGMEYLASQ
181 KCIHRDLAAR  NVLVTENNVN  KIADFGGLAR  INNIDYYKKT  TNGRLPVKWM  APEALFDRVY
241 THQSDVWSFG  VLMWEIFTLG  GSPYPGIPVE  ELFKLLKEGH  RMDKPANCTN  ELYMMMRDCW
301 HAVPSQRPTF  KQLVEDLDRI  LTLTTNEEYL

```

Recombinant FGFR2 nucleotide sequence:

```

1  atgcatcatc  accatcacca  tgaattcaaa  ggcttacgtc  gacaagacac  ccccatgctg
61  gcaggggtct  ccgagtatga  acttcagag  gacccaaaat  gggagtttcc  aagagataag
121 ctgacactgg  gcaagcccc  gggagaaggt  tgctttgggc  aagtgggtcat  ggcggaagca
181 gtgggaattg  acaaagacaa  gcccaaggag  gcggtcaccg  tggccgtgaa  gatgttgaaa
241 gatgatgcca  cagagaaaga  cttttctgat  ctggtgtcag  agatggagat  gatgaagatg
301 attgggaaac  acaagaatat  cataaatctt  cttggagcct  gcacacagga  tgggcctctc
361 tatgtcatag  ttgagtatgc  ctctaaaggc  aacctccgag  aatacctccg  agcccgagg
421 ccaccggga  tggagtactc  ctatgacatt  aaccgtgttc  ctgaggagca  gatgaccttc
481 aaggacttgg  tgtcatgcac  ctaccagctg  gccagaggca  tggagtactt  ggcttcccaa
541 aaatgtattc  atcgagattt  agcagccaga  aatgttttgg  taacagaaaa  caatgtgatg
601 aaaatagcag  actttggact  cgccagagat  atcaacaata  tagactatta  caaaaagacc
661 accaatgggc  ggcttcagg  caagtggatg  gctccagaag  ccctgtttga  tagagtatac
721 actcatcaga  gtgatgtctg  gtccctcggg  gtgttaatgt  gggagatctt  cactttaggg
781 ggctcgccct  acccagggat  tcccgaggag  gaacttttta  agctgctgaa  ggaaggacac
841 agaatggata  agccagccaa  ctgcaccaac  gaactgtaca  tgatgatgag  ggactgttgg
901 catgcagtgc  cctccagag  accaacgttc  aagcagttgg  tagaagactt  ggatcgaatt
961 ctactctca  caaccaatga  ggaatacttg  taa

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services